am 580 has been researched along with Experimental Mammary Neoplasms in 1 studies
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, Y | 1 |
| Bertran, S | 1 |
| Samuels, TA | 1 |
| Mira-y-Lopez, R | 1 |
| Farias, EF | 1 |
1 other study available for am 580 and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cell Proliferation; Cell Transformation | 2010 |